MedKoo product information:

 ARRY-614

Description of Arry-614: ARRY-614  is an orally bioavailable small-molecule inhibitor of p38 and Tie2 kinases with potential antineoplastic, anti-inflammatory and antiangiogenic activities. p38/Tie2 kinase inhibitor Arry-614 binds to and inhibits the activities of p38 and Tie2 kinases, which may inhibit the production of proinflammatory cytokines and may decrease tumor angiogenesis and tumor cell growth and survival. p38 is a MAP kinase that is often upregulated in cancer cells, playing a crucial part in the production of a variety of cytokines involved in inflammation and cellular proliferation such as tumor necrosis factor (TNF) and interleukin (IL)-1 and -6. Tie2 is an endothelial cell specific receptor that is activated by angiopoietins, growth factors required for angiogenesis. This agent has also been reported to inhibit other kinases including vascular endothelial growth factor receptor (VEGFR2) and Src tyrosine kinases. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).

Current developer:    Arraybiopharma

 1. Methods of using small compounds such as glatiramer acetate and mitogen activated protein (MAP) kinase inhibitors to enhance myeloid derived suppressor cell function for treating autoimmune diseases, By Chen, Shu-Hsia  From PCT Int. Appl. (2011), WO 2011087795 A2 20110721.

2. Selective p38α Inhibitors Clinically Evaluated for the Treatment of Chronic Inflammatory Disorders, By Goldstein, David M.; Kuglstatter, Andreas; Lou, Yan; Soth, Michael J.
From Journal of Medicinal Chemistry (2010), 53(6), 2345-2353.

3. Methods using TNF pathway modulators for treating polycystic kidney disease (PKD) or other cyst-forming diseases By Li, Rong; Li, Xiaogang From PCT Int. Appl. (2009), WO 2009045397 A1 20090409.

4. P38 alpha as a therapeutic target in bladder carcinoma By Bernard-Pierrot, Isabelle; Radvanyi, Francois; Allory, Yves  From PCT Int. Appl. (2008), WO 2008142031 A1 20081127.

5. P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation  By Bernard-Pierrot, Isabelle; Radvanyi, Francois; Allory, Yves  From Eur. Pat. Appl. (2008), EP 1992344 A1 20081119.

6. Methods for treating polycystic kidney disease (pkd) or other cyst forming diseases
By Li, Rong; Li, Xiaogang  From U.S. Pat. Appl. Publ. (2008), US 20080269123 A1 20081030.